VRNA - Verona Pharma plc

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
5.92
-0.22 (-3.59%)
At close: 3:14PM EDT
Stock chart is not supported by your current browser
Previous Close6.14
Open6.15
Bid0.00 x 1000
Ask0.00 x 900
Day's Range5.92 - 6.15
52 Week Range5.52 - 17.16
Volume5,206
Avg. Volume8,035
Market Cap80.408M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire13 days ago

    Result of AGM

    LONDON, May 07, 2019 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces.

  • GlobeNewswire13 days ago

    Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2b dose-ranging study evaluating nebulized ensifentrine (RPL554) added on to a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”). The Company anticipates reporting data around year end and commencing Phase 3 clinical trials for this indication in 2020.

  • GlobeNewswire13 days ago

    Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019

    Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2.

  • GlobeNewswire18 days ago

    Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

    LONDON, May 02, 2019 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces.

  • GlobeNewswire19 days ago

    Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

    LONDON, May 01, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to.

  • GlobeNewswire19 days ago

    Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the first quarter ended March 31, 2019 on Tuesday, May 7, 2019. Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) on Tuesday, May 7, 2019 to discuss the first quarter financial results and provide a clinical development update.

  • GlobeNewswire25 days ago

    Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019

    LONDON, April 25, 2019 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory.

  • GlobeNewswirelast month

    Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce that the European Patent Office has recently granted an additional key patent relating to its lead development candidate, ensifentrine. The patent provides intellectual property protection throughout Europe out to 2035 for a suspension formulation of ensifentrine (RPL554) suitable for nebulized administration. A corresponding patent has already issued in the US.

  • GlobeNewswire2 months ago

    Grant of Options and RSUs and PDMR Dealings

    LONDON, April 04, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire2 months ago

    Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Company’s management team will present and conduct face-to-face meetings at the H.C. Wainwright Global Life Sciences Conference. Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present on Monday, April 8th at 11:30 am BST. Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

  • GlobeNewswire2 months ago

    PDMR Dealing

    LONDON, March 25, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire2 months ago

    2018 Annual Report and Accounts and Notice of AGM 

    LONDON, March 22, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire2 months ago

    Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director

    LONDON, March 21, 2019 -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire3 months ago

    Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces positive interim efficacy and safety data from part one of a two-part Phase 2 clinical trial of a dry powder inhaler (“DPI”) formulation of ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (“COPD”). The positive data support initiation of the second part of the Phase 2 trial to evaluate the ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment.

  • GlobeNewswire3 months ago

    Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Company’s management team will present and conduct face-to-face meetings at the Cowen and Company 39th Annual Health Care Conference. Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present on Wednesday, March 13th at 10:00 am ET.  A webcast of the presentation will be available on the "events and presentation" page of the "investors" section of Verona Pharma’s website.

  • GlobeNewswire3 months ago

    Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update

    LONDON, Feb. 26, 2019 -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire3 months ago

    Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2018 on Tuesday, February 26, 2019. Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesday, February 26, 2019 to discuss the full year financial results and provide a clinical development update.

  • GlobeNewswire3 months ago

    Verona Pharma to Present at Upcoming Investor Conferences

    LONDON, Feb. 04, 2019 -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing.

  • GlobeNewswire4 months ago

    Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

    LAMA/LABA therapies are commonly used in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (“COPD”). Patients already receiving inhaled corticosteroid (“ICS”) therapy were allowed to continue to receive a stable dose of ICS throughout the study, thus providing additional data on “triple therapy” use.

  • GlobeNewswire4 months ago

    Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that the World Health Organization (“WHO”) approved “ensifentrine” as the recommended International Non-proprietary Name (“INN”) for the company’s drug candidate, RPL554. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have bronchodilator as well as anti-inflammatory properties, and is currently in development for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”), cystic fibrosis (“CF”) and potentially asthma.

  • GlobeNewswire5 months ago

    Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

    Verona Pharma plc (VRP.L) (VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces the expansion of its global clinical development team with the appointment of Kathleen Rickard, MD, as Chief Medical Officer, and Tara Rheault, PhD, MPH, as Vice President of Research and Development Operations and Global Project Management. Drs. Rickard and Rheault will be based in the Company’s U.S. offices from where they will leverage their expertise to help drive global R&D activities.